
ACHV Stock Forecast & Price Target
ACHV Analyst Ratings
Bulls say
Achieve Life Sciences Inc. has an encouraging outlook due to the validated mechanism and robust clinical efficacy of cytisinicline, positioning it as a vital therapy in the smoking and vaping cessation market amidst rising youth usage rates. The projected sales of $1.6 billion, bolstered by the expansion into the vaping label and potential global market reach, highlight significant revenue growth prospects. Furthermore, cytisinicline's favorable safety profile and flexible dosing options enhance patient adherence and may contribute to sustainable share appreciation for Achieve Life Sciences.
Bears say
Achieve Life Sciences faces a negative outlook primarily due to concerns regarding the adoption rate of cytisinicline, despite its approval for smoking cessation treatment. Internal projections indicate that even if cytisinicline gains approval for cigarette smoking, the anticipated sales may fall short, with a revised peak market penetration for vaping declining from 10% to 8%. Additionally, evidence suggests that while cytisinicline shows promising efficacy in reducing nicotine withdrawal effects, the market may be saturated with alternative therapies, hindering the drug's commercial success.
This aggregate rating is based on analysts' research of Achieve Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
ACHV Analyst Forecast & Price Prediction
Start investing in ACHV
Order type
Buy in
Order amount
Est. shares
0 shares